Showing results (1-10 of 54) with videos related to
Sort By:
Pageof 6
Expert Opinion on Therapeutic Patents|September 9, 2017
Deuterated drugs; updates and obviousness analysisGraham S TimminsExpert Opinion on Drug Discovery|October 1, 2019
What are the challenges in commercial non-tuberculous mycobacteria (NTM) drug discovery and how should we move forward?Graham S TimminsTrends in Microbiology|March 25, 2015
Detecting virulence and drug-resistance mycobacterial phenotypes in vivoGraham S TimminsExpert Opinion on Therapeutic Patents|July 29, 2016
Stable isotope biomarker breath tests for human metabolic and infectious diseases: a review of recent patent literatureGraham S TimminsExpert Opinion on Therapeutic Patents|July 30, 2014
Deuterated drugs: where are we now?Graham S TimminsMolecular Microbiology|November 1, 2006
Mechanisms of action of isoniazidGraham S Timmins, Vojo DereticExpert Opinion on Drug Metabolism & Toxicology|February 6, 2019
Enhancement of lung levels of antibiotics by ambroxol and bromhexineVojo Deretic, Graham S TimminsJournal of Breath Research|May 17, 2019
Potential for breath test diagnosis of urease positive pathogens in lung infectionsWilliam R Bishai, Graham S TimminsPharmacology & Therapeutics|March 23, 2007
Melanoma, long wavelength ultraviolet and sunscreens: controversies and potential resolutionsLeslie P Lund, Graham S TimminsJournal of Bacteriology|August 5, 2004
Requirements for nitric oxide generation from isoniazid activation in vitro and inhibition of mycobacterial respiration in vivoGraham S Timmins, Sharon Master, Frank Rusnak, et al.Pageof 6